Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)open access
- Authors
- Kim, Dong Hyun; Son, Sang Wook; Jeong, Ki-Heon; Ahn, Jiyoung; Lee, Eun-So; Kim, Il-Hwan; Ha Lee, Un; Park, Hai-Jin; Ko, Joo Yeon; Kim, Byung-Soo; Kim, Jin Ju; Rashid, Javed; Kim, Kwang Joong
- Issue Date
- Apr-2023
- Publisher
- KOREAN DERMATOLOGICAL ASSOC
- Keywords
- Adalimumab; Health-related quality of life; Psoriasis
- Citation
- ANNALS OF DERMATOLOGY, v.35, no.2, pp 107 - 115
- Pages
- 9
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- ANNALS OF DERMATOLOGY
- Volume
- 35
- Number
- 2
- Start Page
- 107
- End Page
- 115
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185857
- DOI
- 10.5021/ad.22.041
- ISSN
- 1013-9087
2005-3894
- Abstract
- Background: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations.Objective: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis.Methods: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM.Results: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00-80.00) and 12.40 (range 2.70-39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted.Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registra tion number (clinicaltrials.gov: NCT03099083).
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 피부과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.